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Inhibitory Effect of Polypodium Leucotomos Extract on Cytochrome 
P450 3A-mediated Midazolam Metabolism
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Abstract : Polypodium leucotomos（PL）is a fern native to Latin America, and its 
extract is used as an oral sunscreen ; however, its safety during use has not been 
adequately investigated.  Therefore, the aim of this study was to evaluate food-
drug interactions associated with PL extract mediated by cytochrome P450 3A
（CYP3A）inhibition and induction.  Inhibition of CYP3A-mediated midazolam
（MDZ）1’-hydroxylation activity by PL extract and its major phenolic components 
was evaluated in vitro using pooled human liver microsomes.  In addition, MDZ 
pharmacokinetics were investigated in rats after a single dose, as well as after 1 
week treatment with PL extract（30 mg / kg）in order to evaluate the inhibitory 
and inducible effects of PL on CYP3A in vivo, respectively.  Serum MDZ concen-
trations were analyzed and pharmacokinetic parameters were compared between 
PL- and water（control）-treated groups.  In vitro, PL extract decreased MDZ 
1’-hydroxylation activity in a concentration-dependent manner.  However, the major 
phenolic compounds in PL extracts, namely caffeic, chlorogenic, p-coumaric, ferulic, 
and vanillic acids, did not exhibit any marked inhibitory effects on MDZ 1’-hydrox-
ylation activity.  In vivo, administration of a single dose of PL extract to rats 
signicantly increased the area under the serum concentration-time curve from time 
0 to infinity（AUC0–∞）and the maximum serum concentration（Cmax）of MDZ
（by 57％ and 88％, respectively ; P＜0.05）.  In contrast, there were no signicant 
changes in MDZ pharmacokinetic parameters after 1 week of treatment with PL 
extract.  These results suggest that PL extract can cause a food-drug interaction by 
inhibiting CYP3A.
Key words : food-drug interaction, cytochrome P450, Polypodium leucotomos, 
CYP3A
Introduction
　Sunscreens are widely used to protect against exposure to ultraviolet（UV）radiation, which 
causes sunburn, photoaging, and skin cancer.  However, sunscreen needs to be reapplied 
frequently, and is difficult to use to achieve a demonstrably adequate effect.  Therefore, oral 
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supplements have recently attracted attention as an alternative and easier method of sunburn 
prevention than topical application1）.
　Polypodium leucotomos（PL）is a fern native to Latin America, and its extract is expected to 
have photoprotective benefits through its antioxidative, chemoprotective, immunomodulatory, and 
anti-inflammatory effects2）.  The major active ingredients of PL are phenolic compounds, such as 
caffeic, chlorogenic, and ferulic acids, which are effective for the treatment of vitiligo, chloasma, 
and polymorphous light eruption, as well as in the prevention of skin cancer2—8）.  In Japan, PL 
extract is easily purchased as an oral supplement on Internet shopping sites and in drugstores, 
so its use has become widespread.  Therefore, it is possible that PL extract and other medicines 
may be taken simultaneously, but the safety of the combined use of PL with other medications 
has not been studied.  
　It is well known that drug-drug interactions may occur, and these need to be considered 
when coadministering multiple drugs.  These drug-drug interactions may attenuate the effects of 
coadministered medicines or cause unexpected adverse effects, and so attention should be paid 
to avoid such interactions.  Induction and inhibition of cytochrome P450（CYP）, a typical drug-
metabolizing enzyme, are considered major causes of drug-drug interactions.  Cytochrome P450 
3A（CYP3A）, a CYP isoform, is expressed not only in the liver, but also in the small intestine, 
and it is involved in the metabolism of many drugs, including erythromycin, cyclosporine, and 
nifedipine.  Therefore, CYP3A is important when considering drug-drug interactions9—11）.  
　In addition to drug-drug interactions, several food-drug interactions have been identified.  For 
example, grapefruit juice（GFJ）has been reported to inhibit CYP3A in the small intestine, 
thereby increasing blood concentrations of coadministered nifedipine, with a 1.5-fold increase in 
the area under the serum concentration-time curve（AUC）12）.  In contrast, St. John’s Wort（SJW）
is known to induce hepatic and small intestinal CYP3A, markedly lowering blood concentrations 
of simvastatin and decreasing its AUC by approximately half 13）.  Therefore, the effectiveness and 
safety of medicines may be altered in combination with foods.  However, information regarding 
such potential interactions is currently limited.  Because supplements are classified as “food” 
in Japan, it is not a legal requirement to conduct research on potential interactions between 
supplements and drugs.  However, to prevent clinical adverse events, it is important to clarify 
potential food-drug interactions associated with CYP3A, which is involved in the metabolism of 
many drugs.
　Although recently PL extract has become widely used by people of all generations as a 
simple and alternative method to the administration of sunscreen, its safety in combination with 
medicines has not been investigated.  Against this background, the present study was conducted 
to clarify food-drug interactions mediated by inhibition and induction of CYP3A by PL extract.
Material and methods 
Chemicals
　Heliocare, which contains 240 mg PL extract in each capsule（480 mg）, was purchased from 
Ferndale Healthcare（Ferndale, MI, USA）.  Caffeic, chlorogenic, and vanillic acids were purchased 
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from Tokyo Chemical Industry（Tokyo, Japan）and p-coumaric and ferulic acids were purchased 
from Sigma-Aldrich（St. Louis, MO, USA）.  Midazolam（MDZ）maleate was a kind gift from 
Nippon Roche（Tokyo, Japan）.  MDZ injection（Dormicum injection 10 mg / 2 ml）was purchased 
from Astellas Pharma（Tokyo, Japan）, 1’-hydroxymidazolam was purchased from Daiichi Pure 
Chemicals（Tokyo, Japan）, and diazepam and nitrazepam were purchased from Wako Pure 
Chemical Industries（Osaka, Japan）.  Pooled human liver microsomes were purchased from the 
Non Profit Organization Human and Animal Bridging Research Organization（Chiba, Japan）. 
All other chemicals used were of analytical grade.
Assay of CYP3A activity
　An in vitro study was undertaken to investigate the inhibitory effect of PL extract and its 
major phenolic components, namely caffeic, chlorogenic, p-coumaric, ferulic, and vanillic acids, 
on CYP3A-mediated MDZ 1’-hydroxylation（MDZ 1’-OH）activity using pooled human liver 
microsomes.  
　Heliocare was suspended in distilled water to a concentration of 240 mg / ml PL extract, 
vortexed for 5 min, centrifuged at 1,600 × g for 10 min at room temperature, and the resultant 
supernatant was collected and considered as a 100％ extract solution.  Then, the solution was 
diluted with distilled water to final concentrations ranging from 2.5％ to 10％ and used for in 
vitro experiments ; the five phenolic compounds were used at final concentrations ranging from 5 
to 500 µg / ml.
　The reaction mixtures consisted of pooled human liver microsomes（100 µg）, 10 µM MDZ, 
and the nicotinamide adenine dinucleotide phosphate（NADPH）-generating system in 80 mM 
phosphate buffer（pH 7.4）.  Mixtures were incubated at 37°C for 5 min in the presence of 
either PL extract or any of the five phenolic compounds at the different concentrations tested. 
Reactions were quenched by the addition of a mixture of cold methanol : acetonitrile（35 : 21）, 
and then nitrazepam（200 ng）was added as an internal standard.  Then, 1’-hydroxymidazolam 
was analyzed using HPLC according to the methods of Wrighton and Ring 14）.  Control activity 
was determined under the same conditions with reaction mixtures containing water instead of 
PL extract or phenolic compounds.  Results are expressed as a percentage of control activity. 
Inhibition constant（Ki）values and inhibition modes were determined for PL extract.
　In addition, a preincubation study was performed to determine whether metabolic 
intermediates produced from the PL extract components inactivate CYP3A.  In these studies, PL 
extract（1.25％）was preincubated with pooled human liver microsomes at 37°C for 10, 20, or 
30 min in the presence or absence of NADPH.  After the preincubation step, 10 µM MDZ was 
added and MDZ 1’-OH activity was assayed as described above.
Animals
　Male Sprague-Dawley rats weighing 200–230 g were obtained from Japan Laboratory Animals
（Tokyo, Japan）.  Rats were housed in a temperature-controlled room under a 12-h light-dark 
cycle with free access to standard laboratory chow and water.  Rats were starved overnight 
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before the day of the pharmacokinetic experiments.  The study procedures were reviewed 
and approved by the Showa University Ethics Committee for Animal Care and Use and the 
experiments were conducted in accordance with guidelines established by the Institutional Animal 
Care and Use Committee of Showa University（Permit no.07002）and the Guide for the Care 
and Use of Laboratory Animals（8th edition）of the National Institutes of Health（NIH）https://
grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf, accessed 2017-6-14）.
Treatment and sampling
　In the single treatment study, PL extract（30 mg / kg ; corresponding to 60 mg / kg Heliocare）
or water（control）was administered orally to rats（n＝3—4）30 min before oral administration 
of MDZ（15 mg / kg）.  In the 1-week treatment study, rats（n＝6）were treated with PL extract
（30 mg / kg）or water orally once a day for 1 week, and MDZ was administered 24 h after the 
last administration of extract or water.  Blood samples（200 µl）were collected from the jugular 
vein before and at 15, 30, 45, 60, 90, 120, 180, and 240 min after MDZ administration.  Samples 
were centrifuged at 7,500 × g for 10 min at 4°C, and each serum sample was stored at -80°C 
until analysis.  
　After blood sampling of rats treated for 1 week with PL extract, the rats were killed and 
their livers and small intestines excised.  Liver and intestinal microsomes were prepared using 
a conventional fractional centrifugation method15） and previously described methods with minor 
modifications 16, 17）, respectively.  All microsomal fractions were frozen with liquid nitrogen and 
stored at -80°C until use.  Protein concentrations were measured using the method of Lowry et 
al 18）.  
　
MDZ pharmacokinetic analysis
　MDZ serum concentrations were determined using previously described HPLC methods19—21）
with slight modifications.  The pharmacokinetic parameters of MDZ were assessed using non-
compartmental analysis with MOMENT（Excel ; Microsoft, Bellevue, WA, USA）based on the 
moment analytic method22, 23）.  The AUC from time 0 to infinity（AUC0–∞）was calculated 
according to the trapezoidal rule.  The maximum serum concentration（Cmax）was obtained from 
the actual data.  The elimination half-life（t½）was calculated by dividing ln2 byλ, which is the 
terminal elimination rate constant calculated using a linear regression analysis of at least three 
points from the terminal portion of the concentration-time plot.
Ex vivo study
　Liver and intestinal microsomes, prepared 1 day after the last administration of PL extract 
in the 1-week treatment study, were used in the ex vivo study.  Because MDZ is known to be 
predominantly metabolized to 4-hydroxymidazolam and, to a lesser extent, 1’-hydroxymidazolam 
by hepatic and intestinal CYP3A in rats, we analyzed MDZ 4-hydroxylation（MDZ 4-OH）
activity as described previously 24, 25）.  
33Effect of Polypodium Leucotomos on CYP3A
Statistical analyses
　In vitro data are expressed as mean values of experiments performed in duplicate.  Data from 
in vivo and ex vivo experiments are presented as the mean ± SD.  The significance of differences 
between the groups was analyzed using the Mann-Whitney U-test and two-sided P＜0.05 was 
considered significant.
Results
CYP3A activity in vitro
　PL extract inhibited CYP3A-mediated MDZ 1’-OH activity in pooled human liver microsomes 
in a concentration-dependent manner.  Lineweaver-Burk plots showed that the inhibition 
mode was competitive with a Ki of 3.33％（Figure 1A）.  In contrast, the five major phenolic 
compounds contained in PL extract, namely caffeic, chlorogenic, p-coumaric, ferulic, and vanillic 
acids, did not exhibit any marked inhibitory effects on CYP3A activity（Figure 2）.  
　To determine whether PL possibly forms metabolic intermediates that inhibit CYP3A activity 
during incubation, MDZ 1’-OH activity was assayed by including a 10- to 30-min preincubation 
step.  The results of these experiments showed that including the preincubation step did not 
increase the inhibition of MDZ 1’-OH activity by PL extract（Figure 1B）.
Pharmacokinetics of MDZ
　Serum MDZ concentration-time profiles and pharmacokinetics 30 min after a single treatment 
with PL extract or water（control）are shown in Figure 3 and Table 1.  The mean AUC0–∞ of 
MDZ increased from 480 ± 102 to 755 ± 61 ng·hr/ml per h, and the Cmax increased from 462 ± 125 
to 871 ± 164 ng/ml（P＜0.05 vs control）, without any change in t½ .  In contrast, in the 1-week 
treatment study, there were no significant differences in serum concentrations, AUC0–∞ , Cmax, or t½ 
Fig. 1.  Inhibitory effect of Polypodium leucotomos（PL）extract on cytochrome P450 3A（CYP3A）activity in vitro
（A）The direct inhibitory effect of PL extract was investigated using a Lineweaver-Burk plot.
（B）Effect of preincubation with PL extract （1.25％） on midazolam 1’-hydroxylation（MDZ 1’-OH）activity 
in the presence（closed circles）or absence（opened circles） of NADPH. Data show mean values of 
experiments performed in duplicate or triplicate.




Fig. 2.  Inhibitory effect of the major components of Polypodium leucotomos （PL） 
extract on midazolam 1’-hydroxylation （MDZ 1’-OH） activity in vitro
Components were added to the incubation mixture at final concentrations of 
5-500 µg / ml. Data are mean values of experiments performed in duplicate. CAA, 
caffeic acid; CHA, chlorogenic acid; FEA, ferulic acid; pCA, p-coumaric acid; VAA, 
vanillic acid.
Table 1.   Pharmacokinetic parameters of midazolam（MDZ）after a single treat-
ment with Polypodium leucotomos（PL）extract in rats
AUC0–∞（ng·hr / ml） Cmax（ng / ml） t½（min）
Control 480 ± 102 462 ± 125 30 ± 4
PL extract 755 ± 61＊ 871 ± 164＊ 40 ± 15
Data are the mean ± SD of three to four rats. 
＊P＜ 0.05 compared with control.
AUC0–∞, area under the serum concentration-time curve from time 0 to innity; 
Cmax, maximum serum concentration; t½, half-life.
ml
Fig. 3.  Serum concentration-time profile of midazolam（MDZ） after treatment of 
rats with a single dose of Polypodium leucotomos（PL）extract    
Rats were administered PL extract（30 mg / kg）or water （control）orally 30 min 
before oral administration of MDZ（15 mg / kg）. Data show the mean ± SD of three 
to four rats.
35Effect of Polypodium Leucotomos on CYP3A
of MDZ between the PL- and water-treated groups（Figure 4 ; Table 2）.
CYP activity ex vivo
　After 1 week of treatment with PL, there were no significant differences in CYP3A-mediated 
MDZ 4-OH activity between the PL- and water-treated groups in either liver microsomes（922.82 ± 
247.61 vs 1,090.93± 136.32 pmol / mg protein per min ; Figure 5A）or intestinal microsomes（22.78±
11.35 vs.  28.46 ± 22.08 pmol / mg protein per min ; Figure 5B）.
Discussion
　In the present study we investigated the inhibitory and inducing effects of PL extract on 
CYP3A to clarify potential food-drug interactions mediated by this enzyme.  The results revealed 
that PL extract inhibited CYP3A-mediated MDZ metabolism both in vitro and in vivo.
　First, our investigation of the inhibitory effect of PL extract on MDZ 1’-OH activity in human 
liver microsomes in vitro showed competitive inhibition of CYP3A activity.  The extract primarily 
Fig. 4.  Serum concentration-time profiles of midazolam（MDZ） after 1 week of 
treatment of rats with Polypodium leucotomos（PL）extract
Rats were pretreated with PL extract（30 mg / kg）or water（control）once a 
day for 1 week, and MDZ （15 mg / kg） was then administered orally 24 h after 
administration of the last dose of PL extract. Data are the mean ± SD of six rats.
Table 2.   Pharmacokinetic parameters of midazolam（MDZ）after 1 week treat-
ment of rats with Polypodium leucotomos（PL）extract
AUC0–∞（ng·hr/ml） Cmax（ng/ml） t½（min）
Control 831 ± 274 712 ± 309 37 ± 11
PL extract 603 ± 146 542 ± 215 37 ±  6
Data are the mean ± SD of six rats.
AUC0–∞, area under the serum concentration-time curve from time 0 to innity; 
Cmax, maximum serum concentration; t½, half-life.
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contains phenolic compounds, such as caffeic, chlorogenic, ferulic, hydroxycinnamic, p-coumaric, 
and vanillic acids, which have been reported to be the active ingredients mediating the sunscreen 
effect of PL extract 2）.  To investigate whether these compounds are involved in PL-induced 
inhibition of CYP3A, we examined the CYP3A-inhibiting activity of each of the compounds 
separately.  In contrast with PL extract, none of the phenolic compounds significantly inhibited 
CYP3A activity.  The concentration range of the compounds used in this study（5-500 µg / ml）is 
considered sufficiently high based on estimated amounts transported in the blood after treatment 
with PL extract 26）.  Therefore, the lack of any significant inhibition of CYP3A by these five 
compounds suggests that other components of PL extract likely contributed to its inhibition of 
CYP3A.
　The Heliocare used in this study contains 240 mg PL extract and it is recommended that 1-2 
capsules be consumed per day.  Although the types of ingredients and their amounts entering 
the blood after administration of PL extract are not known, we could assume that there are 
relatively high concentrations in the small intestine, indicating that possible drug interactions 
via intestinal CYP3A inhibition should be considered.  In the present in vitro study, because 
the PL extract was suspended in water, as described in the Materials and Methods, and the 
supernatant was considered to be a 100％ PL extract, we consider that there are likely to be 
fewer ingredients, in lower amounts, than that actually ingested after taking a Heliocare capsule. 
Therefore, it is fully conceivable that the inhibition of CYP3A observed in vitro was the result 
of treatment with the PL extract.
　In this study, we also performed in vivo experiments using rats to clarify whether this CYP3A-
mediated food-drug interaction occurs in vivo.  Following treatment with a single dose of PL 
extract, there were significant increases in both the ACU0–∞ and Cmax of MDZ compared with 
the control group.  However, it should be noted that the 60 mg / kg dose of Heliocare used in 
our in vivo study（30 mg / kg as PL extract）was 7.5-fold higher than the usual dose in humans. 
However, efficacious drug doses are generally higher in rats than in humans.  Therefore, the 
Fig. 5.  Effects of 1 week treatment of rats with Polypodium leucotomos（PL）
extract on cytochrome P450 3A （CYP3A）activity    
Rats were pretreated with PL extract（30 mg / kg）or water（control）once a day 
for 1 week, and liver and small intestine microsomes were prepared 1 day after the 
last treatment.  Midazolam 4-hydroxylation（MDZ 4-OH）activity was analyzed in
（A）liver and（B）small intestine microsomes. Data are the mean ± SD of six rats.
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dose of PL extract used in the present study was based on a previous report investigating 
the antioxidant effect of PL extract against UVB/UVA in rats 27）.  The results of the present 
study suggest that PL extract also increases blood MDZ concentrations in vivo by inhibiting 
CYP3A activity.  Recently, PL extract has attracted attention as a sunscreen supplement and 
there are concerns about its coadministration with medicines.  Because CYP3A is involved in 
the metabolism of many drugs, precautions are needed to avoid the development of unexpected 
adverse effects, especially with medicines that have a narrow therapeutic range.
　In addition, mechanism-based inhibition（MBI）is a known mechanism of CYP inhibition. 
MBI is important clinically because the metabolic intermediates metabolized by CYP are 
irreversibly bound, resulting in potent and sustained inhibition.  A typical example of MBI 
occurs with GFJ, known to inactivate CYP3A irreversibly with an effect that lasts at least for 3 
days12, 28）.  Therefore, we conducted an in vitro study including a preincubation step to investigate 
the possible occurrence of MBI with PL extract.  However, no further inhibition of MDZ 1’-OH 
was observed when PL extract was preincubated with human liver microsomes and NADPH 
before the addition of MDZ.  Therefore, we concluded that the mechanism by which PL extract 
inhibits CYP3A activity is direct rather than involving MBI.
　PL extract may be ingested as a single treatment, but it is used for long periods for sun 
protection, especially in the summer season.  Therefore, it is important to investigate food-drug 
interactions via induction of CYP3A in addition to the inhibitory effects of PL extract.  For 
example, blood concentrations of simvastatin have been reported to be markedly decreased 
as a result of the induction of CYP3A by SJW13）.  In such situations, cotreatment with this 
supplement should be avoided because it may decrease the efficacy of medicines metabolized by 
this enzyme.  Our examination of the potential induction of CYP3A by a 1-week of treatment 
of rats with PL extract showed no significant differences in the pharmacokinetic parameters of 
MDZ administered 24 h after the final PL administration compared with the control group.  In 
addition, there were no changes in either liver or small intestine CYP3A activity after 1 week 
treatment with PL extract, suggesting that PL extract did not induce CYP3A.  Meanwhile, in the 
1-week treatment study, because MDZ was administered 24 h after the last dose of PL extract, 
it seems that the components had already been eliminated and no inhibition of CYP3A was 
observed.  Further studies are needed to clarify the inhibitory effects of multiple doses of PL 
extract on CYP3A-mediated drug metabolism.
　Recently, the self-medication concept has been expanding in Japan, and the use of herbal 
supplements has increased among the population.  However, knowledge and information 
regarding the safety of the combined use of herbal supplements and conventional medicines is 
considered insufficient.  Thus, the investigation of possible food-drug interactions is important for 
the safe and effective use of herbal supplements, which is the motivation for the present study. 
It is important to clarify whether the results of the present in vitro and in vivo rat experiments 
also occur in humans.  In addition, experiments are needed to provide similar information on 
other CYP isoforms, such as CYP2C9 and CYP2D6, which metabolize many important medicines 
used clinically.
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　In conclusion, PL extract, which has recently drawn attention as a sunscreen supplement, 
inhibited CYP3A activity, indicating the possibility of increased blood concentrations of 
coadministered medicines that are metabolized by this enzyme.  In contrast, PL extract was 
shown to be less likely to cause drug interactions as a result of CYP3A induction.
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